IHC News and Research

RSS

Researchers develop novel technique for detecting ALK rearrangements in non-small cell lung cancers

Researchers have developed a novel technique for detecting ALK rearrangements in non-small cell lung cancers (NSCLCs) that is more sensitive and easier to perform than currently available techniques.

25 Feb 2014

Study: Recurrence of SCCOP may differ in HPV-positive and HPV-negative patients

Patients with HPV-positive squamous cell carcinoma of the oropharynx (SCCOP) had a longer time to development of distant metastasis (DM) after initial treatment, and had more metastatic sites in more atypical locations compared to HPV-negative patients, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

HPV-positive patients with OPSCC show higher overall survival rate than HPV-negative patients

A retrospective analysis of oropharyngeal patients with recurrence of disease after primary therapy in the Radiation Therapy Oncology Group (RTOG) studies 0129 or 0522 found that HPV-positive patients had a higher overall survival (OS) rate than HPV-negative patients (at two years post-treatment, 54.6 percent vs. 27.6 percent, respectively), according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

20 Feb 2014

New collaboration aims to push cancer diagnostics to the next level

A collaboration between National Cancer Centre Singapore and Clearbridge BioMedics, in partnership with the Pathology Department at Singapore General Hospital has resulted in the establishment of the region's first Circulating Tumour Cell Centre of Research Excellence. This new Centre facilitates the use of circulating tumour cells in clinical diagnostics, in order for new technologies to be applied by healthcare institutions.

19 Jan 2014

Genomic tests help in selecting the most effective therapy for breast cancer

Genomic tests that determine the molecular subtype of a woman's breast cancer provide a more precise prognosis and valuable guidance about the best treatment, according to new research led by Massimo Cristofanilli, M.D, Director of the Jefferson Breast Care Center at the Kimmel Cancer Center (KCC) and Thomas Jefferson University and Hospitals.

13 Dec 2013

Report: Screen all endometrial cancer patients for Lynch syndrome

A recent article by Norris Cotton Cancer Center researchers published in the January 2014 issue of the journal Clinical Chemistry reviews the scientific evidence that warrants screening all endometrial cancers for Lynch syndrome. Next to colorectal cancer, endometrial cancer is the most common form of cancer in women with Lynch syndrome.

12 Dec 2013

Scientists target protein-detection approach to systematically measure human repertoire of proteins

An international team of scientists led by Fred Hutchinson Cancer Research Center cancer proteomics expert Amanda Paulovich, M.D., has demonstrated the feasibility of large-scale, standardized protein measurements, which are necessary for validation of disease biomarkers and drug targets.

9 Dec 2013

Ventana now offers FDA-cleared image analysis and digital read application for IHC breast markers

Ventana Medical Systems, Inc., a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration for the Companion Algorithm ER (SP1) image analysis algorithm used with the VENTANA iScan Coreo scanner running Virtuoso software. With this clearance, Ventana is now the only company in the industry offering a comprehensive portfolio of FDA-cleared image analysis algorithms and digital read applications for the five key immunohistochemistry breast markers.

5 Dec 2013

Experts develop new working formulation for reporting of cardiac antibody-mediated rejection

Antibody-mediated rejection of the transplanted heart is a recognized clinical complication and a major limitation to survival of patients who have undergone heart transplantation. Experts have now developed a new working formulation for the pathologic diagnosis, grading, and reporting of cardiac antibody-mediated rejection.

18 Nov 2013

Measuring BMI can help predict diabetic patient's risk for heart disease

Researchers from the Intermountain Medical Center Heart Institute, in collaboration with researchers from Johns Hopkins University and the National Institutes of Health, have discovered a simple way to further predict a diabetic patient's risk for heart disease: by measuring their body mass index or BMI.

17 Nov 2013

Leica Biosystems launches new Novocastra HD menu for hematopathology

Leica Biosystems announces the launch of the fourth Novocastra HD menu, focused on hematopathology. Previously launched were the Novocastra HD menus for breast, head & neck and dermatopathology.

12 Nov 2013

Ventana partners with Incyte to develop companion diagnostic tests for oncology drug programs

Ventana Medical Systems, Inc., a member of the Roche Group, today announced that it has entered into an agreement with Incyte Corporation to collaborate on the development of companion diagnostic tests for Incyte's oncology drug programs, beginning with the Incyte IDO1 inhibitor program.

5 Nov 2013

Scientists identify new algorithm to distinguish two subtypes of malignant melanoma

Scientists of the University of Ulm and Columbia University have discovered a diagnostic algorithm to distinguish two subtypes of malignant melanoma. Desmoplastic and spindle cell melanoma may look alike - they often resemble little scars or retractions of the skin - but differ in prognosis and therapeutic options.

4 Nov 2013

EZH2 protein may aid prognostication in resected NSCLC

A protein called “enhancer of zeste homolog-2” is frequently expressed in non-small-cell lung cancer and may have prognostic value following surgical resection, US researchers believe.

30 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

Researchers develop new method to identify genes involved in kidney diseases

Understanding how genes act in specific tissues is critical to our ability to combat many human diseases, from heart disease to kidney failure to cancer. Yet isolating individual cell types for study is impossible for most human tissues.

5 Oct 2013

Study suggests relationship between smoking history, response to inhibiting PD-L1/PD-1 pathway

New results from a trial of an antibody that helps the immune system to recognise and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers.

30 Sep 2013

Ventana, Boehringer Ingelheim to develop companion diagnostic tests for oncology programs

Ventana Medical Systems, Inc., a member of the Roche Group, and Boehringer Ingelheim announced today that they have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs.

19 Sep 2013

Current criteria for ALK positive lung cancer needs to be redefined

A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. The findings suggest that doctors should look closer at borderline or atypical ALK-negative cases, and could widen the population of lung cancer patients offered treatment with crizotinib or other ALK-inhibitor drugs.

12 Sep 2013

High resolution of U‐SPECT/CT system helps perform kinetic analyses of viral spread in vivo

The ability to visualize and analyze the spread of viral infections in primary and metastatic tumors is an essential component in characterizing the therapeutic efficacy of oncolytic viruses.